Equities research analysts predict that ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) will announce earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for ASLAN PHARMACEUTICALS ADR REP 5’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.30). The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that ASLAN PHARMACEUTICALS ADR REP 5 will report full-year earnings of ($1.36) per share for the current fiscal year, with EPS estimates ranging from ($1.48) to ($1.25). For the next year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.80) to ($1.09). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for ASLAN PHARMACEUTICALS ADR REP 5.

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.06).

A number of research firms have recently commented on ASLN. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research note on Tuesday, July 3rd. Piper Jaffray Companies began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set an “overweight” rating on the stock. Zacks Investment Research lowered ASLAN PHARMACEUTICALS ADR REP 5 from a “buy” rating to a “sell” rating in a research report on Tuesday, August 7th. Leerink Swann began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “market perform” rating and a $7.00 target price on the stock. Finally, BTIG Research began coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “buy” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.94.

ASLN opened at $7.80 on Tuesday. ASLAN PHARMACEUTICALS ADR REP 5 has a one year low of $5.08 and a one year high of $10.44.

Institutional investors have recently made changes to their positions in the company. MYDA Advisors LLC acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth $195,000. Temasek Holdings Private Ltd acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth $12,660,000. Finally, Platinum Investment Management Ltd. acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth $2,532,000. 10.93% of the stock is currently owned by institutional investors.

ASLAN PHARMACEUTICALS ADR REP 5 Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.

Further Reading: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on ASLAN PHARMACEUTICALS ADR REP 5 (ASLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN)

Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.